Proteasomal Targeting and Minigene Repetition Improve Cell-Surface Presentation of a Transfected, Modified Melanoma Tumour Antigen

Scandinavian Journal of Immunology

Volumn 59, Issue 2, 2004, Pages 220-227

  Rasmussen, A B ^a   Zocca, M B ^a   Bonefeld, C M ^a   Von Essen, M ^a   Lauritsen, J P H ^a   Tomra, S ^a   Odum N ^a   Geisler, C ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYSTEINE PROTEINASE; DNA VACCINE; EPITOPE; MELAN A PROTEIN; MELAN-A PROTEIN; MELANOMA ANTIGEN RECOGNIZED BY T CELL 1; MULTIENZYME COMPLEX; PEPTIDE; PROTEASOME; TUMOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; CELL LINE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY TEST; DENSITY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GENETICS; HUMAN; HUMAN CELL; IMMUNOLOGY; MELANOMA; MOLECULAR GENETICS; NUCLEOTIDE REPEAT; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CANCER VACCINES; CELL LINE; CYSTEINE ENDOPEPTIDASES; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; MULTIENZYME COMPLEXES; NEOPLASM PROTEINS; PLASMIDS; POLYMERASE CHAIN REACTION; PROTEASOME ENDOPEPTIDASE COMPLEX; REPETITIVE SEQUENCES, NUCLEIC ACID; T-LYMPHOCYTES; TRANSFECTION; VACCINES, DNA;

EID: 1342267609     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0300-9475.2004.01374.x     Document Type: Article

References (30)

1. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
2. Coulie PG, Brichard V, Van Pel A et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
3. Romero P, Gervois N, Schneider J et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997;159:2366-74.
4. Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
5. Pittet MJ, Valmori D, Dunbar PR et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-15.
6. Wang F, Bade E, Kuniyoshi C et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-65.
7. Rosenberg SA, Zhai Y, Yang JC et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-900.
8. Jaeger E, Bernhard H, Romero P et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996;66:162-9.
9. Cormier JN, Salgaller ML, Prevette T et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
10. + T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003;9:657-62.
11. Valmori D, Dutoit V, Schnuriger V et al. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol 2002;168:4231-40.
12. Valmori D, Fonteneau JF, Valitutti S et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol 1999;11:1971-80.
13. + T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res 1999;59:301-6.
14. Kim DT, Rothbard JB, Bloom DD, Fathman CG. Quantitative analysis of T cell activation: role of TCR/ligand density and TCR affinity. J Immunol 1996;156:2737-42.
15. Wherry EJ, Puorro KA, Porgador A, Eisenlohr LC. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol 1999;163:3735-45.
16. Bullock TN, Colella TA, Engelhard VH. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J Immunol 2000;164:2354-61.
17. Vijh S, Pilip IM, Pamer EG. Effect of antigen-processing efficiency on in vivo T cell response magnitudes. J Immunol 1998;160:3971-7.
18. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999;17:739-79.
19. Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol 2000;18:538-43.
20. Rodriguez F, Zhang J, Whitton JL. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997;71:8497-503.
21. Delogu G, Howard A, Collins FM, Morris SL. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 2000;68:3097-102.
22. Leachman SA, Shylankevich M, Slade MD et al. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 2002;76:7616-24.
23. Wu Y, Kipps TJ. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J Immunol 1997;159:6037-43.
24. Grant EP, Michalek MT, Goldberg AL, Rock KL. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol 1995;155:3750-8.
25. Liu WJ, Zhao KN, Gao FG et al. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 2001;20:862-9.
26. Xiang R, Lode HN, Chao TH et al. An autologous oral DNA vaccine protects against murine melanoma. Proc Natl Acad Sci USA 2000;97:5492-7.
27. Montoya M, Del Val M. Intracellular rate-limiting steps in MHC class I antigen processing. J Immunol 1999;163:1914-22.
28. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235-46.
29. Valitutti S, Muller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996;183:1917-21.
30. Anton LC, Yewdell JW, Bennink JR. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. J Immunol 1997;158:2535-42.